This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc., a subsidiary of Helsinn Healthcare SA, is a prominent player in the biopharmaceutical industry, headquartered in the United States. Founded in 1977, the company has established itself as a leader in the development of innovative therapies for cancer and other serious medical conditions, with a strong focus on supportive care. With operational regions spanning North America and beyond, Helsinn is renowned for its unique portfolio of products, including anti-emetics and treatments aimed at improving the quality of life for patients undergoing cancer therapies. The company’s commitment to research and development has led to significant milestones, including the successful launch of several key products that address unmet medical needs. Helsinn Therapeutics is recognised for its strategic partnerships and robust market position, making it a trusted name in the healthcare sector, dedicated to enhancing patient outcomes through science-driven solutions.
DitchCarbon Score
How does Helsinn Therapeutics (U.S.), Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Helsinn Therapeutics (U.S.), Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Helsinn Therapeutics (U.S.), Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Helsinn Healthcare S.A., which may influence its climate commitments and performance metrics. As of now, Helsinn Therapeutics has not established any documented reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). This lack of specific commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data and reduction initiatives, it is essential to monitor Helsinn Therapeutics' future climate commitments and performance, particularly as it aligns with the broader sustainability goals of its parent company, Helsinn Healthcare S.A.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 1,175,000 | 00,000 |
| Scope 2 | 340,000 | 000 |
| Scope 3 | 1,855,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Helsinn Therapeutics (U.S.), Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
